Precision BioSciences, Inc. (Ticker: DTIL) is a pioneering gene editing company headquartered in Durham, North Carolina, dedicated to developing transformative therapeutic solutions for a range of diseases. Leveraging its proprietary ARCUS genome editing technology, the company is at the forefront of creating targeted genetic therapies aimed at addressing significant unmet medical needs in oncology, genetic disorders, and infectious diseases. With a strong pipeline of innovative treatments and a commitment to advancing precision medicine, Precision BioSciences is strategically positioned to lead advancements in the biopharmaceutical sector, delivering impactful patient outcomes while enhancing the future of healthcare. Show more

Location: 302 EAST PETTIGREW ST., DURHAM, NC, UNITED STATES, 27701, Durham, NC, 27701, USA | Website: https://precisionbiosciences.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

95.32M

52 Wk Range

$3.75 - $8.82

Previous Close

$3.98

Open

$3.98

Volume

225,084

Day Range

$3.83 - $4.02

Enterprise Value

80.18M

Cash

44.87M

Avg Qtr Burn

-15.27M

Insider Ownership

5.87%

Institutional Own.

44.52%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ECUR-506 Details Ornithine transcarbmylase deficiency	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBGENE-HBV Details Chronic hepatitis B	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details Cancer, B-cell lymphoma, Diffuse large B cell lymphoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR19B (CD19 Allogeneic CAR-T) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBGENE-DMD Details Duchenne Muscular Dystrophy (DMD)	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR269A (BCMA) Details Cancer, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PBCAR20A (targeting CD20) Details Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.